246 related articles for article (PubMed ID: 16690529)
1. Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group.
Van Der Jagt R; Robinson KS; Belch A; Yetisir E; Wells G; Larratt L; Shustik C; Gluck S; Stewart K; Sheridan D;
Leuk Lymphoma; 2006 Apr; 47(4):697-706. PubMed ID: 16690529
[TBL] [Abstract][Full Text] [Related]
2. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
[TBL] [Abstract][Full Text] [Related]
3. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
[TBL] [Abstract][Full Text] [Related]
4. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
[TBL] [Abstract][Full Text] [Related]
5. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
6. Etoposide in acute leukemia. Past experience and future perspectives.
Ho AD; Brado B; Haas R; Hunstein W
Cancer; 1991 Jan; 67(1 Suppl):281-4. PubMed ID: 1984828
[TBL] [Abstract][Full Text] [Related]
7. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia.
Maslak PG; Weiss MA; Berman E; Yao TJ; Tyson D; Golde DW; Scheinberg DA
Leukemia; 1996 Jan; 10(1):32-9. PubMed ID: 8558934
[TBL] [Abstract][Full Text] [Related]
9. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor.
Kalaycio M; Pohlman B; Elson P; Lichtin A; Hussein M; Tripp B; Andresen S
Am J Clin Oncol; 2001 Feb; 24(1):58-63. PubMed ID: 11232951
[TBL] [Abstract][Full Text] [Related]
11. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Spagnoli A; Voso MT; Fianchi L; Papayannidis C; Gaidano GL; Breccia M; Musto P; De Bellis E; Del Principe MI; Lunghi M; Lessi F; Martinelli G; Venditti A
Ann Hematol; 2018 Oct; 97(10):1767-1774. PubMed ID: 29947973
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG).
Lowenthal RM; Bradstock KF; Matthews JP; Bishop JF; Juneja S; Cobcroft R; Eliadis P; Enno A; Gill D; Herrmann RP; Manoharan A; Page FJ; Rooney KF; Rosenfeld D; Seldon M; Taylor KM; Wolf MM; Young GA
Leuk Lymphoma; 1999 Aug; 34(5-6):501-10. PubMed ID: 10492073
[TBL] [Abstract][Full Text] [Related]
14. Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia.
Beksaç M; Arslan O; Koç H; Akan H; Ilhan O; Arat M; Ozcan M; Gürman G; Konuk N; Uysal A
Med Oncol; 1998 Sep; 15(3):183-90. PubMed ID: 9819795
[TBL] [Abstract][Full Text] [Related]
15. GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly.
Pierri I; Clavio M; Beltrami G; Cavaliere M; Lanza L; Miglino M; Canepa L; Pietrasanta D; Ballerini F; Quintino S; Gatto S; Celesti L; Carrara P; Varese P; Gobbi M
J Exp Clin Cancer Res; 1999 Mar; 18(1):55-60. PubMed ID: 10374678
[TBL] [Abstract][Full Text] [Related]
16. Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.
Jehn U; Suciu S; Thomas X; Lefrère F; Muus P; Berneman Z; Marie JP; Adamo F; Fillet G; Nobile F; Ricciuti F; Leone G; Rizzoli V; Montanaro M; Beeldens F; Fazi P; Mandelli F; Willemze R; de Witte T; Amadori S
Leukemia; 2006 Oct; 20(10):1723-30. PubMed ID: 16932345
[TBL] [Abstract][Full Text] [Related]
17. [Outcomes of adult patients with
Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2018 Jan; 39(1):15-21. PubMed ID: 29551027
[No Abstract] [Full Text] [Related]
18. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
[TBL] [Abstract][Full Text] [Related]
19. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia.
Archimbaud E; Fenaux P; Reiffers J; Cordonnier C; Leblond V; Travade P; Troussard X; Tilly H; Auzanneau G; Marie JP
Leukemia; 1993 Mar; 7(3):372-7. PubMed ID: 8445942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]